Evidence map›Paper›PMID 39591152›Full record

ArticleVaccines2024

Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

Khalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, Matthias Reinscheid, Sebastian Giese, Kevin Ciminski, Georg Kochs, Martin Schwemmle, Julia Lang-Meli, Michelle Maas and 20 more

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Khalid ShoumariyehDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0001-7969-1972
Benedikt CsernalabicsDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Elahe Salimi AlizeiDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Matthias ReinscheidDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Sebastian GieseInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Kevin CiminskiInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0001-5397-7497
Georg KochsInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Martin SchwemmleInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0002-2972-6855
Julia Lang-MeliDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Michelle MaasDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Natascha RoehlenDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Vivien KarlDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0001-7026-7622
Anne GraeserDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Oezlem SogukpinarDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Ivana von MetzlerDepartment of Medicine II-Hematology and Oncology, Goethe-University Frankfurt, University Hospital, 60629 Frankfurt am Main, Germany.ORCID 0000-0003-1699-4313
Denise GrathwohlDepartment of Internal Medicine II, University of Würzburg, 97070 Würzburg, Germany.
Leo RascheDepartment of Internal Medicine II, University of Würzburg, 97070 Würzburg, Germany.
Holger HebartClinics Ostalb, Stauferklinikum, 73557 Mutlangen, Germany.
Miriam KullDepartment of Internal Medicine III, Ulm University Hospital, 89081 Ulm, Germany.
Florian EmmerichInstitute for Transfusion Medicine and Gene Therapy, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0002-1099-9634
Cornelius Florian WallerDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0002-5777-0212
Justus DuysterDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0001-7325-7753
Monika EngelhardtDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0003-0405-1676
Tanja Nicole HartmannDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0002-0377-7179
Bertram BengschGerman Cancer Consortium (DKTK), Partner Site Freiburg, a Partnership Between DKFZ and University Medical Center Freiburg, 79098 Freiburg, Germany.
Tobias BoettlerDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Christoph Neumann-HaefelinDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0001-7351-1387
Maike HofmannDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0001-8410-8833
Robert ThimmeDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.
Hendrik LuxenburgerDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79098 Freiburg, Germany.ORCID 0000-0001-7182-8620

Funding

Deutsche Forschungsgemeinschaft 256073931Deutsche Forschungsgemeinschaft 272983813Deutsche Forschungsgemeinschaft 413517907Deutsche Forschungsgemeinschaft 441891347Deutsche Forschungsgemeinschaft 505372148Deutsche Forschungsgemeinschaft 520992132Deutschen Konsortium für Translationale Krebsforschung 01-424-SOBDeutschen Konsortium für Translationale Krebsforschung FR01-SOB-SHO (1020000424)Federal Ministry of Education and Research 01EO2103Helmholtz Association's Initiative and Networking Fund KA1-Co-02 "COVIPA"
6 · The paper itself

Abstract

backgroundMultiple myeloma (MM) patients are at high risk of severe infections including COVID-19 due to an immune dysregulation affecting both innate and adaptive immune responses. However, our understanding of the immune responses to infection and vaccination in MM patients is limited. To gain more detailed insights into infection- and vaccine-elicited T cell immunity in MM, we studied the CD8+ T cell response on the single-epitope level in SARS-CoV-2 convalescent and mRNA-vaccinated MM patients.

methodsWe compared peptide/MHC class I tetramer-enriched SARS-CoV-2-specific CD8+ T cells and antibody responses in MM patients (convalescent:

resultsMM patients have lower frequencies and a lower proportion of fully functional virus-specific CD8+ T cells compared to HCs, after both SARS-CoV-2 infection and vaccination. CD8+ T cell memory subset distribution in MM patients is skewed towards reduced frequencies of central memory (T

conclusionsMM patients have relative immunological deficiencies in SARS-CoV-2 immunity but benefit from hybrid immunity. These findings underline the relevance of vaccinations in this vulnerable patient group.

Indexed as

adaptive immune responseCOVID-19immunosuppressioninfectionmRNA vaccinationmultiple myelomaSARS-CoV-2T cells

Identifiers

PMID39591152
PMCPMC11598869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.